A	C177537	GDC Value Terminology	C171871	Crenigacestat	An orally available inhibitor of the integral membrane protein gamma-secretase (GS), with potential antineoplastic activity. Upon administration, crenigacestat binds to the GS protease complex, thereby blocking the proteolytic cleavage and release of the Notch intracellular domain (NICD), which would normally follow ligand binding to the extracellular domain of the Notch receptor. This prevents both the subsequent translocation of NICD to the nucleus to form a transcription factor complex and the expression of Notch-regulated genes. This results in the induction of apoptosis and the inhibition of growth in tumor cells that overexpress Notch. Overexpression of the Notch signaling pathway plays an important role in tumor cell proliferation and survival.	Gamma-Secretase Inhibitor LY3039478 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C40141	Wolffian Tumor	An adnexal epithelial neoplasm of Wolffian (mesonephric) origin. It predominantly affects the broad ligament and presents as a unilateral adnexal mass. Most tumors behave in a benign fashion.	9110/0 | morphology || 9110/1 | morphology || Mesonephric adenoma | primary_diagnosis || Mesonephric tumor, NOS | primary_diagnosis || Mesonephroma, NOS | primary_diagnosis || Mesonephroma, benign | primary_diagnosis || Mesonephromas | disease_type || Wolffian duct adenoma | primary_diagnosis || Wolffian duct tumor | primary_diagnosis	C176985 || C177621 || C2991	morphology || primary_diagnosis || disease_type
A	C177537	GDC Value Terminology	C40206	Human Papillomavirus-Independent Cervical Adenocarcinoma, Gastric-Type	Cervical adenocarcinoma characterized by the presence of gastric differentiation. It is not associated with human papillomavirus infection.	8483/3 | morphology || Mucinous carcinoma, gastric type | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C1097	Exemestane	An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.	Exemestane | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C116377	Osimertinib	A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.	Osimertinib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C118573	GS/pan-Notch Inhibitor AL102	An orally bioavailable, gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, GS/pan-Notch inhibitor AL102 binds to GS and blocks the proteolytic cleavage and release of the Notch intracellular domain (NICD), which would normally follow ligand binding to the extracellular domain of the Notch receptor. This prevents both the subsequent translocation of NICD to the nucleus to form a transcription factor complex and the expression of Notch-regulated genes. This results in the induction of apoptosis and the inhibition of growth of tumor cells that overexpress Notch. Overexpression of the Notch signaling pathway plays an important role in tumor cell proliferation and survival. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains and leads to their activation.	GS/pan-Notch Inhibitor BMS-986115 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C120183	Eltrapuldencel-T	A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, eltrapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.	Melapuldencel-T | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C124229	Bintrafusp Alfa	A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.	Bintrafusp Alfa | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C127907	Endocervical Adenocarcinoma, Usual-Type	A cervical adenocarcinoma in which 0-50% of malignant cells contain intracytoplasmic mucin. It is the most common subtype of cervical adenocarcinoma and represents 75% of all invasive cervical adenocarcinomas. The neoplastic epithelium shows a pseudostratified architecture and the malignant cells have enlarged, elongated, and hyperchromatic nuclei. Historically, usual-type cervical adenocarcinomas were termed endocervical-type.	8384/3 | morphology || 8482/3 | morphology || Adenocarcinoma, endocervical type | primary_diagnosis || Endocervical adenocarcinoma usual type | primary_diagnosis || Mucinous adenocarcinoma, endocervical type | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C129717	Vebreltinib	An orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, vebreltinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.	Bozitinib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C131335	Temuterkib	An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, temuterkib inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.	ERK1/2 Inhibitor LY3214996 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C146660	Mezigdomide	A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T-cells. This leads to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.	Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C148507	Anti-EGFR/DM1 Antibody-drug Conjugate AVID100	A targeted antibody drug conjugate (ADC) consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of AVID100 binds to  EGFR on tumor cell surfaces. Following receptor internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.	Anti-EGFR/DM1 Antibody-drug Conjugate AVID100 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C150248	ERK1/2 Inhibitor ERAS-007	An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERAS-007 specifically binds to and inhibits the serine/threonine-protein kinase activities of both ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.	ERK1/2 Inhibitor ASN007 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C151951	Trotabresib	An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, trotabresib preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.	BET Inhibitor CC-90010 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C155878	Relmacabtagene Autoleucel	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Autologous CD19-targeted CAR T Cells JWCAR029 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158074	Vusolimogene Oderparepvec	A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells only while not infecting normal, healthy cells. This induces tumor cell lysis. The released virus particles, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. The released tumor-associated antigens (TAAs) from the tumor cells activate the immune system to exert an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. In RP1, ICP34.5 and 47 proteins of the HSV1 strain have been deleted; RP1 expresses a fusogenic protein for optimal tumor cell infection and killing.	Oncolytic Virus RP1 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158558	Azercabtagene Zapreleucel	A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) with potential immunostimulating and antineoplastic activities. Upon administration, azercabtagene zapreleucel specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.	Allogeneic Anti-CD19-CAR T-cells PBCAR0191 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158617	Pirtobrutinib	An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.	BTK Inhibitor LOXO-305 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158750	Pegsitacianine	A micellar polymer tracer labeled with the near-infrared (NIR) fluorescent imaging dye indocyanine green (ICG), with potential fluorescent imaging activity. Upon administration, pegsitacianine accumulates in tumor tissue. The micelles dissociate and subsequently fluoresce upon exposure to the acidic conditions of the tumor microenvironment (TME), allowing the visualization of tumors using infrared-based cameras.	Indocyanine Green-labeled Polymeric Micelles ONM-100 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C160293	Enterococcus gallinarum Strain MRx0518	A live strain of the flagellin-producing Gram-positive bacterium Enterococcus (E.) gallinarum that is isolated from a healthy human gut , with potential immunomodulating and antineoplastic activities. Upon oral administration, MRx0518 modulates the intestinal microbiota and targets both intestinal epithelial cells (IECs), and various immune cells, such as macrophages and dendritic cells (DCs)  and is able to induce the production of both pro- and anti-inflammatory mediators, such as interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-a), IL-1beta, IL-6, IL-23, in these cells and activates the innate immune system. The flagellin produced by MRx0518 interacts with and activates toll-like receptor 5 (TLR5), thereby activating the adaptive immune system and modulating the tumor microenvironment (TME). This activates the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against tumor cells.	Enterococcus gallinarum Strain MRx0518 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C160603	Camizestrant	An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.	Selective Estrogen Receptor Degrader AZD9833 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C162532	Multiple Kinase Inhibitor TT-00420	An orally available small molecule inhibitor of Aurora kinases (AKs) A and B, Janus kinases (JAKs), fibroblast growth factor receptors (FGFRs) and vascular endothelial growth factor receptors (VEGFRs), with potential antineoplastic and immunomodulatory activities. Upon oral administration, multiple kinase inhibitor TT-00420 selectively binds to and inhibits AKs A and B, which inhibit cell division in tumor cells that overexpress AKs. TT-00420 also targets JAKs that are involved in cytokine signaling and inflammation, and FGFRs and VEGFRs, which  are overexpressed in the microenvironment (TME) and contribute to neovascularization, tumor growth and metastasis.  These kinases are overexpressed by a wide variety of cancer cell types and drive tumor cell proliferation.	Aurora kinase A/B inhibitor TT-00420 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C162573	Luxeptinib	An orally bioavailable reversible, pan-inhibitor of both FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) and Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon oral administration, luxeptinib targets, non-covalently binds to and inhibits the activity of both FLT3, including both wild-type (WT) FLT3 and FLT3-ITD (internal tandem duplications), tyrosine kinase domain (FLT3-TKD), and gatekeeper (FLT3-F691L) mutant forms, and BTK, including both the WT and its C481S mutant (BTK-C481S) form. This inhibits both uncontrolled FLT3-mediated and B-cell antigen receptor (BCR)-mediated signaling, respectively. This results in the inhibition of proliferation in tumor cells overexpressing FLT3 and BTK. In addition, CG-806 also inhibits, to a lesser degree, other oncogenic kinases, such as MET, RET, discoidin domain-containing receptor 2 (DDR2), Aurora kinase A, and interleukin-2-inducible T-cell kinase (ITK). FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs), and plays a key role in tumor cell proliferation. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases essential to BCR signaling, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.	Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C165507	Zevorcabtagene Autoleucel	A preparation of autologous T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a humanized single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) that is fused to the co-stimulatory domain of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, zevorcabtagene autoleucel specifically recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells.	Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C172746	Obecabtagene Autoleucel	A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR), CAT-41BBz CAR, targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, obecabtagene autoleucel target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The CAT-41BBz CAR has a faster off-rate compared with FMC63-41BBz CAR. This may minimize cytokine release and reduce toxicities, and enhance persistence of the CAR T-cells.	Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173415	EGFR Mutant-selective Inhibitor TQB3804	A fourth-generation, orally bioavailable, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor TQB3804 binds to and inhibits the activity of mutant forms of EGFR, including the C797S EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. TQB3804 inhibits mutated forms of EGFR including C797S, which prevents covalent bond formation with third-generation EGFR inhibitor osimertinib leading to drug resistance. TQB3804 may have enhanced anti-tumor effects in tumors with C797S-mediated resistance when compared to other EGFR tyrosine kinase inhibitors.	EGFR Mutant-selective  Inhibitor TQB3804 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173725	Frenlosirsen	An antisense oligonucleotide (ASO) targeting the interferon regulatory factor 4 (IRF4) mRNA, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, frenlosirsen hybridizes with IRF4 mRNA, which blocks translation of the IRF4 protein. Reduction of IRF4 levels prevents the expression of IRF4-controlled tumor promoter genes, and may enhance tumor cell apoptosis and prevent T-cell exhaustion. IRF4, a transcription factor expressed in lymphocytes and essential for plasma cell differentiation, is involved in immune cell development and plays a key role in T-cell functions. It is overexpressed in certain tumor cell types and is a key regulator of multiple genes controlling tumor cell survival.	Anti-IRF4 Antisense Oligonucleotide ION251 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173877	Taniraleucel	A population of cryopreserved, off-the-shelf (OTS) allogeneic natural killer (NK) cells derived from human placental hematopoietic stem cells (HSCs) and expressing the CD56 surface antigen and exhibiting a lack of CD3, with potential immunomodulating, antineoplastic and antiviral activities. Upon infusion of taniraleucel, these cells are able to recognize tumor cells as well as virally-infected cells, secrete perforins, granzymes and cytokines, and induce apoptosis in tumor and virally-infected cells.	Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C200	Acetylcysteine	A synthetic N-acetyl derivative and prodrug of the endogenous amino acid L-cysteine, a precursor of the antioxidant glutathione (GSH), with mucolytic, antioxidant, and potential cytoprotective, cancer-preventive, and anti-inflammatory activities.  Upon administration, acetylcysteine exerts its mucolytic activity by reducing disulfide bonds in mucoproteins, resulting in liquification of mucus and reducing its viscosity. It is also used for the treatment of acetaminophen overdose as it can restore the depleted GSH reserves in the hepatocytes during the process of detoxification.  The antioxidant activity is attributed to the ability of GSH to scavenge reactive oxygen species (ROS), thereby preventing ROS-mediated cell damage, decreasing oxidative stress, protecting cells against the damaging effects of free radicals and preventing apoptosis in these cells. In addition, this may inhibit tumor cell proliferation, progression and survival, in susceptible tumor cells that rely on ROS-mediated signaling for their proliferation and malignant behavior. Under certain circumstances, acetylcysteine is able to induce apoptosis in susceptible cells, including certain tumor cells, via the intrinsic mitochondria-dependent pathway but not involving endoplasmic reticulum stress. Also, acetylcysteine may also be able to degrade Notch2, thereby preventing proliferation, migration, and invasion in Notch2-overexpressing glioblastoma cells. In addition, acetylcysteine may inhibit viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. Acetylcysteine also possesses anti-inflammatory activity through modulation of the nuclear factor-kappa B (NF-kB) pathway and the modulation of cytokine synthesis.	Acetylcysteine | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C24401	CEP43 Gene	This gene is involved in the regulation of cell shape, polarity and motility.	FGFR1OP | gene_symbol || FGFR1OP | second_gene_symbol	C171253 || C43568	second_gene_symbol || gene_symbol
C	C177537	GDC Value Terminology	C27683	Human Papillomavirus-Related Squamous Cell Carcinoma	A squamous cell carcinoma associated with the presence of human papillomavirus infection.	Squamous cell carcinoma, HPV-positive | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C3446	Primary Immune Thrombocytopenia	Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).	ITP | comorbidity	C16457	comorbidity
C	C177537	GDC Value Terminology	C3726	Adenomyoma	A benign neoplasm characterized by the presence of a glandular and a mesenchymal (fibromyomatous) component. It occurs in the uterine corpus, cervix, and uterine ligaments. A variant of adenomyoma associated with glandular architectural complexity is called atypical polypoid adenomyoma. Simple polypectomy is usually curative. Atypical polypoid adenomyoma may recur following polypectomy.	8932/0 | morphology || Adenomyoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3757	Placental Site Trophoblastic Tumor	A rare gestational trophoblastic tumor characterized by the presence of a diffuse cellular infiltrate composed of intermediate trophoblasts and cytotrophoblasts and by the absense of a significant population of syncytiotrophoblasts.	9104/1 | morphology || Placental site trophoblastic tumor | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C38701	Lutetium Lu 177 Rosopatamab Tetraxetan	A radioimmunoconjugate consisting of rosopatamab, a humanized monoclonal antibody (MoAb) against the external domain of the prostate-specific membrane antigen (PSMA) that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during single-photon emission computerized tomography/computerized tomography (SPECT/CT). Upon administration, lutetium Lu 177 rosopatamab tetraxetan binds to PSMA expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PSMA-expressing cells. PSMA is overexpressed in the malignant prostate and its metastases.	Lutetium Lu 177 Monoclonal Antibody J591 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C40017	Rete Ovarii Adenocarcinoma	An exceptionally rare adenocarcinoma that arises from the rete ovarii.	9110/3 | morphology || Adenocarcinoma of rete ovarii | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C40173	Uterine Corpus Metastasizing Leiomyoma	A cytologically benign smooth muscle neoplasm that arises from the uterine corpus and has metastasized to the lungs, abdomen, or lymph nodes. It usually presents in women with a history of benign uterine leiomyomas that have been surgically removed years before the extrauterine neoplasm spread.	8898/1 | morphology	C176985	morphology
C	C177537	GDC Value Terminology	C4072	Mesonephric Adenocarcinoma	An adenocarcinoma of the cervix or the vagina that derives from Wolffian duct remnants and shows mesonephric differentiation.	9110/3 | morphology || Mesonephric adenocarcinoma | primary_diagnosis || Mesonephroma, malignant | primary_diagnosis || Wolffian duct carcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C54204	Lower Gingiva	The gingiva covering the mandibular alveolar bone.	Lower gum | progression_or_recurrence_anatomic_site || Lower gum | site_of_resection_or_biopsy || Lower gum | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C54205	Upper Gingiva	The gingiva covering the maxillary alveolar bone.	Upper Gum | tissue_or_organ_of_origin || Upper gum | progression_or_recurrence_anatomic_site || Upper gum | site_of_resection_or_biopsy	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C62600	Davamotecan Pegadexamer	A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based linear polymer with potential antineoplastic activity. Upon intravenous administration of davamotecan pegadexamer, camptothecin is slowly released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to camptothecin alone, the cyclodextrin-based polymer formulation has a prolonged half life and greatly improves the biodistribution of camptothecin resulting in an accumulation of camptothecin at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects. In addition, cyclodextrin-based polymer-camptothecin may be able to overcome certain kinds of multidrug resistance.	Cyclodextrin-Based Polymer-Camptothecin CRLX101 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C9039	Cervical Carcinoma	A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are squamous cell carcinoma and adenocarcinoma.	Cervical Cancer | relationship_primary_diagnosis || Cervical Cancer (all types) | tumor_code	C177615 || C178243	tumor_code || relationship_primary_diagnosis
C	C177537	GDC Value Terminology	C95209	Guadecitabine	A dinucleotide antimetabolite composed of a decitabine linked via phosphodiester bond to a deoxyguanosine, with potential antineoplastic activity. Following metabolic activation via cleavage of the phosphodiester bond and incorporation of the decitabine moiety into DNA, guadecitabine inhibits DNA methyltransferase, thereby causing non-specific, genome-wide hypomethylation, and induction of cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, which may result in gradual release of decitabine both extra- and intra-cellularly, leading to prolonged exposure to decitabine.	Guadecitabine | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C121535	Gamma-Secretase Inhibitor LY3039478	An orally available inhibitor of the integral membrane protein gamma-secretase (GS), with potential antineoplastic activity. Upon administration, gamma-secretase inhibitor LY3039478 binds to the GS protease complex, thereby blocking the proteolytic cleavage and release of the Notch intracellular domain (NICD), which would normally follow ligand binding to the extracellular domain of the Notch receptor. This prevents both the subsequent translocation of NICD to the nucleus to form a transcription factor complex and the expression of Notch-regulated genes. This results in the induction of apoptosis and the inhibition of growth in tumor cells that overexpress Notch. Overexpression of the Notch signaling pathway plays an important role in tumor cell proliferation and survival.	Gamma-Secretase Inhibitor LY3039478 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C127905	Cervical Mucinous Adenocarcinoma, Gastric Type	A cervical mucinous adenocarcinoma showing gastric differentiation.	Mucinous carcinoma, gastric type | primary_diagnosis	C177621	primary_diagnosis
D	C177537	GDC Value Terminology	C4294	Benign Mesonephroma	A benign epithelial neoplasm of the female reproductive system arising from mesonephric remnants.	9110/0 | morphology || Mesonephric adenoma | primary_diagnosis || Mesonephroma, benign | primary_diagnosis || Wolffian duct adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C4295	Mesonephric Neoplasm	An epithelial neoplasm of the female reproductive system arising from mesonephric remnants.	9110/3 | morphology || Mesonephric tumor, NOS | primary_diagnosis || Mesonephroma, NOS | primary_diagnosis || Mesonephromas | disease_type || Wolffian duct tumor | primary_diagnosis	C176985 || C177621 || C2991	morphology || primary_diagnosis || disease_type
D	C177537	GDC Value Terminology	C66951	Adenocarcinoma, Endocervical Type	An adenocarcinoma characterized by the presence of malignant glandular epithelium resembling the endocervical epithelium.	8384/3 | morphology || Adenocarcinoma, endocervical type | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C66953	Mucinous Adenocarcinoma, Endocervical Type	A mucinous adenocarcinoma characterized by the presence of malignant glandular cells which resemble the endocervical epithelium.	8482/3 | morphology || Mucinous adenocarcinoma, endocervical type | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis